Advances in the development of AMPK-activating compounds

Expert Opinion on Drug Discovery

Volumn 3, Issue 10, 2008, Pages 1167-1176

  Sriwijitkamol, Apiradee ^a,b,c   Musi, Nicolas ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Texas Diabetes Institute   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

A 769662; ACC; AICAR; AMPK; Metformin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; A 592107; A 769662; ANTIDIABETIC AGENT; BERBERINE; COMBRETASTATIN A4; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; POLYPHENOL DERIVATIVE; RESVERATROL; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CHOLESTEROL SYNTHESIS; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SYNTHESIS; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW;

EID: 55049121166     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.10.1167     Document Type: Review

References (100)

1. Defronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37(6):667-87
2. Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990;322(4):223-8
3. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(Suppl 3):35-45
4. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4(5):517-40
5. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113(12):909-15
6. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995;16(2):117-42
7. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998;182(1-2):3-11
8. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997;46(3):524-7
9. Caro JF, Sinha MK, Raju SM, et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 1987;79(5):1330-7
10. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105(3):311-20
11. Goodyear LJ, Giorgino F, Sherman LA, et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995;95(5):2195-204
12. Zierath JR, Krook A. Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM. Mol Cell Biochem 1998;182(1-2):153-60
13. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001;50(7):1612-7
14. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108(3):437-46
15. Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999;48(8):1600-6
16. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002;51(7):2005-11
17. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insullin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999;274(34):24202-10
18. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293(5535):1673-7
19. Bergeron R, Russell RR 3rd, Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 1999;276(5 Pt 1):E938-44
20. Hayashi T, Hirshman MF, Kurth EJ, et al. Evidence for 5′AMP-activated protein kinasc mediation of the effect of muscle contraction on glucose transport. Diabetes 1998;47(8):1369-73
21. Mu J, Brozinick JT Jr, Valladares O, et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 2001;7(5):1085-94
22. Musi N, Fujii N, Hirshman MF, et al. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 2001;50(5):921-7
23. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273(6 Pr 1):E1107-12
24. Fisher JS, Gao J, Han DH, et al. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol 2002;282(1):E18-23
25. Iglesias MA, Ye JM, Frangioudakis G, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51(10):2886-94
26. Furnsinn C, Neschen S, Noe C, et al. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Br J Pharmacol 1997;122(7):1367-74
27. Kemp BE, Mitchelhill KI, Stapleton D, et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999;24(1):22-5
28. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem FEBS 1997;246(2):259-73
29. Stapleton D, Woollatt E, Mitchelhill KI, et al. AMP-activated protein kinase isoenzyme Family: subunit structure and chromosomal location. FEBS Lett 1997;409(3):452-6
30. Stapleton D, Mitchethill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271(2):611-4
31. Woods A, Azzout-Marniche D, Foretz M, et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000;20(18):6704-11
32. Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996;271(44):27879-87
33. Crute BE, Seefeld K, Gamble J, et al. Functional domains of the alphal catalytic subunit of the AMP-activated protein kinase. J Biol Chem 1998;273(52):35347-54
34. Hudson ER, Pan DA, James J, et al. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol 2003;13(10):861-6
35. Polekhina G, Gupta A, Michell BJ, et al. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol 2003;13(10):867-71
36. Polekhina G, Gupta A, Van Denderen BJ, et al. Structural basis for glycogen recognition by AMP-activated protein kinase. Structure 2005;13(10):1453-62
37. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem Sci 1997;22(1):12-3
38. Kemp BE. Bateman domains and adenosine derivatives form a binding contract. J Clin Invest 2004;113(2):1824
39. Scott JW, Hawley SA, Green KA, et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004;113(2):274-84
40. Sanders MJ, Grondin PO, Hegarty BD, et al. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007;403(1):13948
41. Hawley SA, Boudeau J, Reid JI, et al. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2(4):28
42. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13(22):2004-8
43. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2(1):9-19
44. Hurley RL, Anderson KA, Franzone JM, et al. The Ca2+/ calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005;280(32):29060-6
45. Woods A, Dickerson K, Heath R, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005;2(1):21-33
46. Ruderman NB, Saba AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999;276(1 Pt 1):E1-18
47. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 1996;270 (2 Pt 1):E299-304
48. Rutter GA, Da Silva Xavier G, Leclerc I. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003;375(Pt 1):1-16
49. Wasserman DH, Halseth AE. An overview of muscle glucose uptake during exercise. Sites of regulation. Adv Exp Med Biol 1998;441:1-16
50. Winder WW. Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 2001;91(3):1017-28
51. Frosig C, Jorgensen SB, Hardie DG, et al. 5′-AMP-acdvated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle. Am J Physiol 2004;286(3):E411-7
52. Fujii N, Hirshman MF, Kane EM, et al. AMP-activated protein kinase alpha2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle. J Biol Chem 2005;280(47):39033-41
53. Jorgensen SB, Wojtaszewski JF, Viollet B. et al. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J 2005;19(9):1146-8
54. Jorgensen SB, Viollet B, Andreelli F, et al. Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004;279(2):1070-9
55. Costford SR, Kavaslar N, Ahituv N, et al. Gain-of-function R225W mutation in human AMPKgamma3 causing increased glycogen and decreased triglyceride in skeletal muscle. PLoS One 2007;2(9):e903
56. Vincent MF, Marangos PJ, Gruber HE, et al. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991;40(10):1259-66
57. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167-74
58. Vincent MF, Erion MD, Gruber HE, Van Den Berghe G. Hypoglycaemic effect of AICAriboside in mice. Diabetologia 1996;39(10):1148-55
59. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54(5):1331-9
60. Cotton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem FEBS 1995;229(2):558-65
61. Shimomura I, Matsuda M, Hammer RE, et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6(1):77-86
62. Sullivan JE, Brocklehurst KJ, Marley AE, et al. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 1994;353(1):33-6
63. Bergeron R, Previs SF, Cline GW, et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50(5):1076-82
64. Song XM, Fiedler M, Galuska D, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002;45(1):56-65
65. Buhl ES, Jessen N, Pold R. et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002;51(7):2199-206
66. Musi N, Goodyear LJ. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets 2002;2(2):119-27
67. Cuthbertson DJ, Babraj JA, Mustard KJ, et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007;56(8):2078-84
68. Dixon R, Gourzis J, Mcdermott D, et al. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31(4):342-7
69. Cusi K, Consoli A, Defronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81(11):4059-67
70. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008;57(2):306-14
71. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004;279(46):47898-905
72. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6
73. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51(7):2074-81
74. Luna V, Casauban L, Sajan MP, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia 2006;49(2):375-82
75. El-Mir MY, Nogueira V, Fontaine I, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275(1):223-8
76. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-14
77. Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo Role of mitochondrial reactive nitrogen species. J Biol Chem 2004;279(42):43940-51
78. Xie Z, Dong Y, Scholz R, et al. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008;117(7):952-62
79. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117(5):1422-31
80. Bays H, Mandarino L, Defronzo RA. Role of the adipocyte, free fatty acids, and ectopic Fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a national therapeutic approach. J Clin Endocrinol Metab 2004;89(2):463-78
81. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277(28):25226-32
82. Saha AY, Avilucea PR, Ye JM, et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 2004;314(2):580-5
83. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle Fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99(25):16309-13
84. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288-95
85. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277(1 Pt 1):E1-10
86. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006;3(6):403-16
87. Goransson O, Mcbride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007;282(45):32549-60
88. Sanders MJ, Ali ZS, Hegarty BD, et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007;282(45):32539-48
89. Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr 2005;81(1 Suppl):S292-7
90. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006;55(8):2180-91
91. Breen DM, Sanli T, Giacca A. Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008
92. Park CE, Kim MJ, Lee JH, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007;39(2):222-9
93. Zhang F, San C, Wu J, et al. Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice. Pharmacol Res 2008;57(4):318-23
94. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55(8):2256-64
95. Cheng Z, Pang T, Gu M, et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochimica et biophysica acta 2006;1760(11):1682-9
96. Kim SH, Shin EJ, Kim ED, et al. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm Bull 2007;30(11):2120-5
97. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008;57(5):1414-8
98. Koistinen HA, Galuska D, Chibalin AV, et al. 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 2003;52(5):1066-72
99. De Filippis E, Alvarez G, Berria R, et al. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol 2008;294(3):E607-14
100. Sriwijitkamol A, Coletta DK, Wajcberg F, et al. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 2007;56(3):836-48